Forskning ved Københavns Universitet - Københavns Universitet

Forside

Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). / Pandit, R.; Cianci, D.; ter Hark, S. E.; Winter-van Rossum, I.; Ebdrup, B. H.; Broberg, B. V.; Garcia-Portilla, M. P.; Bobes, J.; Vinkers, C. H.; Kahn, R. S.; Guloksuz, S.; Huitema, A. D.R.; Luykx, J. J.

I: Acta Psychiatrica Scandinavica, Bind 140, Nr. 3, 2019, s. 283-290.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Pandit, R, Cianci, D, ter Hark, SE, Winter-van Rossum, I, Ebdrup, BH, Broberg, BV, Garcia-Portilla, MP, Bobes, J, Vinkers, CH, Kahn, RS, Guloksuz, S, Huitema, ADR & Luykx, JJ 2019, 'Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)', Acta Psychiatrica Scandinavica, bind 140, nr. 3, s. 283-290. https://doi.org/10.1111/acps.13074

APA

Pandit, R., Cianci, D., ter Hark, S. E., Winter-van Rossum, I., Ebdrup, B. H., Broberg, B. V., ... Luykx, J. J. (2019). Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica, 140(3), 283-290. https://doi.org/10.1111/acps.13074

Vancouver

Pandit R, Cianci D, ter Hark SE, Winter-van Rossum I, Ebdrup BH, Broberg BV o.a. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica. 2019;140(3):283-290. https://doi.org/10.1111/acps.13074

Author

Pandit, R. ; Cianci, D. ; ter Hark, S. E. ; Winter-van Rossum, I. ; Ebdrup, B. H. ; Broberg, B. V. ; Garcia-Portilla, M. P. ; Bobes, J. ; Vinkers, C. H. ; Kahn, R. S. ; Guloksuz, S. ; Huitema, A. D.R. ; Luykx, J. J. / Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). I: Acta Psychiatrica Scandinavica. 2019 ; Bind 140, Nr. 3. s. 283-290.

Bibtex

@article{0ec794b631b84876b1ba398d5638c687,
title = "Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)",
abstract = "Objective: Antipsychotic-induced weight gain (AiWG) is a debilitating adverse effect of most antipsychotics. First-episode psychosis patients are particularly vulnerable to the detrimental consequences of AiWG. Amisulpride has good efficacy and tolerability. We here aimed to identify the phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients. Method: Data were collected from the Optimization of Treatment and Management of Schizophrenia in Europe trial. Multivariable regression models with various phenotypic variables (N = 305) were performed with absolute AiWG and clinically relevant AiWG (≥7{\%} AiWG) as outcomes. Results: Four weeks of amisulpride treatment increased body weight from 69.7 to 72.4 kg (P < 0.001). In the regression model of absolute AiWG, unemployment (β = 0.94, P = 0.016), younger age (β = −0.07, P = 0.031) and absence of current comorbid major depression disorder (β = −1.61, P = 0.034) were positively associated with absolute AiWG. In the regression model of clinically relevant AiWG, unemployment (OR = 2.83, P = 0.001), schizophreniform disorder (OR = 2.00, P = 0.025) and low baseline weight (OR = 0.97, P = 0.032) increased the likelihood of clinically relevant AiWG. Conclusions: Clinicians prescribing amisulpride should consider the relatively high susceptibility to AiWG in unemployed first-episode patients with psychosis, in particular young subjects with a diagnosis of schizophreniform disorder. We advise to carefully monitor these patients and, when needed, implement weight-reducing strategies.",
keywords = "amisulpride, antipsychotic, psychosis, schizophrenia, weight gain",
author = "R. Pandit and D. Cianci and {ter Hark}, {S. E.} and {Winter-van Rossum}, I. and Ebdrup, {B. H.} and Broberg, {B. V.} and Garcia-Portilla, {M. P.} and J. Bobes and Vinkers, {C. H.} and Kahn, {R. S.} and S. Guloksuz and Huitema, {A. D.R.} and Luykx, {J. J.}",
year = "2019",
doi = "10.1111/acps.13074",
language = "English",
volume = "140",
pages = "283--290",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

AU - Pandit, R.

AU - Cianci, D.

AU - ter Hark, S. E.

AU - Winter-van Rossum, I.

AU - Ebdrup, B. H.

AU - Broberg, B. V.

AU - Garcia-Portilla, M. P.

AU - Bobes, J.

AU - Vinkers, C. H.

AU - Kahn, R. S.

AU - Guloksuz, S.

AU - Huitema, A. D.R.

AU - Luykx, J. J.

PY - 2019

Y1 - 2019

N2 - Objective: Antipsychotic-induced weight gain (AiWG) is a debilitating adverse effect of most antipsychotics. First-episode psychosis patients are particularly vulnerable to the detrimental consequences of AiWG. Amisulpride has good efficacy and tolerability. We here aimed to identify the phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients. Method: Data were collected from the Optimization of Treatment and Management of Schizophrenia in Europe trial. Multivariable regression models with various phenotypic variables (N = 305) were performed with absolute AiWG and clinically relevant AiWG (≥7% AiWG) as outcomes. Results: Four weeks of amisulpride treatment increased body weight from 69.7 to 72.4 kg (P < 0.001). In the regression model of absolute AiWG, unemployment (β = 0.94, P = 0.016), younger age (β = −0.07, P = 0.031) and absence of current comorbid major depression disorder (β = −1.61, P = 0.034) were positively associated with absolute AiWG. In the regression model of clinically relevant AiWG, unemployment (OR = 2.83, P = 0.001), schizophreniform disorder (OR = 2.00, P = 0.025) and low baseline weight (OR = 0.97, P = 0.032) increased the likelihood of clinically relevant AiWG. Conclusions: Clinicians prescribing amisulpride should consider the relatively high susceptibility to AiWG in unemployed first-episode patients with psychosis, in particular young subjects with a diagnosis of schizophreniform disorder. We advise to carefully monitor these patients and, when needed, implement weight-reducing strategies.

AB - Objective: Antipsychotic-induced weight gain (AiWG) is a debilitating adverse effect of most antipsychotics. First-episode psychosis patients are particularly vulnerable to the detrimental consequences of AiWG. Amisulpride has good efficacy and tolerability. We here aimed to identify the phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients. Method: Data were collected from the Optimization of Treatment and Management of Schizophrenia in Europe trial. Multivariable regression models with various phenotypic variables (N = 305) were performed with absolute AiWG and clinically relevant AiWG (≥7% AiWG) as outcomes. Results: Four weeks of amisulpride treatment increased body weight from 69.7 to 72.4 kg (P < 0.001). In the regression model of absolute AiWG, unemployment (β = 0.94, P = 0.016), younger age (β = −0.07, P = 0.031) and absence of current comorbid major depression disorder (β = −1.61, P = 0.034) were positively associated with absolute AiWG. In the regression model of clinically relevant AiWG, unemployment (OR = 2.83, P = 0.001), schizophreniform disorder (OR = 2.00, P = 0.025) and low baseline weight (OR = 0.97, P = 0.032) increased the likelihood of clinically relevant AiWG. Conclusions: Clinicians prescribing amisulpride should consider the relatively high susceptibility to AiWG in unemployed first-episode patients with psychosis, in particular young subjects with a diagnosis of schizophreniform disorder. We advise to carefully monitor these patients and, when needed, implement weight-reducing strategies.

KW - amisulpride

KW - antipsychotic

KW - psychosis

KW - schizophrenia

KW - weight gain

U2 - 10.1111/acps.13074

DO - 10.1111/acps.13074

M3 - Journal article

C2 - 31323113

AN - SCOPUS:85070432748

VL - 140

SP - 283

EP - 290

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 3

ER -

ID: 231903228